Table 2 Multivariable analysis of OS with PhenoTIL (MAD + MSCC) and clinical variables for each cohort (D1, D2, D3, D4, D5, D6, D7).

From: Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

	Characteristics	Hazard ratio	95% CI	P	n
D1	Gender
	Male	0.48	0.26–0.91	0.025
	Female
	Histologycal Subtpes
	Squamous Cell Carcinoma	0.42	0.21–0.84	0.014	71
	Adenocarcinoma
	Clinical Stage
	I
	II	0.22	0.05–0.94	0.042	66
	III	3.35	0.94–11.92	0.062
	IV	1.44	0.44–4.77	0.55	66
	TNM Staging
	N0
	N1	0.69	0.35–1.36	0.287	59
	T1
	T2	0.82	0.44–1.53	0.535	59
	PhenoTIL
	Low Risk	0.81	0.45–1.46	0.489	71
D2	Gender
	Male	0.39	0.21–0.72	0.003	71
	Female
	Histologycal Subtpes
	Squamous Cell Carcinoma	0.53	0.29–0.99	0.048
	Adenocarcinoma
	Clinical Stage
	I
	II	0.93	0.42–2.00	0.849	70
	III	2.16	0.91–5.12	0.081	70
	IV	3.09	1.04–9.16	0.042
	TNM Staging
	T1
	T2	0.95	0.47–1.93	0.894	54
	T3	0.7	0.15–3.14	0.637	64
	PhenoTIL
	Low Risk	0.43	0.23–0.79	0.006
D3	Gender
	Male	0.45	0.26–0.79	0.005
	Female
	Histologycal Subtpes
	Squamous Cell Carcinoma	0.31	0.17–0.59	<0.001	79
	Adenocarcinoma
	Clinical Stage
	I
	II	0.48	0.21–1.10	0.082	72
	III	2.62	1.23–5.58	0.012
	IV	2.21	0.66–7.44	0.201	72
	PhenoTIL
	Low Risk	0.54	0.31–0.92	0.023	79
D4	Histologycal Subtpes
	Squamous Cell Carcinoma	0.79	0.58–1.07	0.13	376
	Adenocarcinoma
	Clinical Stage
	I
	II	1.07	0.76–1.50	0.714	351
	TNM Staging
	T1
	T2	0.83	0.12–5.92	0.849	376
	PhenoTIL
	Low Risk	0.9	0.71–1.14	0.365
D5	Gender
	Male	1.28	1.03–1.60	0.026
	Female
	Histologycal Subtpes
	Squamous Cell Carcinoma	1.15	0.93–1.42	0.209	850
	Adenocarcinoma
	Clinical Stage
	I
	II	1.94	1.27–2.11	<0.001	838
	III	2.12	1.59–2.81	<0.001	838
	IV	2.72	1.68–4.39	<0.001	838
	TNM Staging
	T1
	T2	1.29	0.99–1.68	0.06	841
	T3	1.96	1.36–2.82	<0.001	841
	T4	3.28	1.98–5.43	<0.001	841
	Tx	3.62	0.89–14.79	0.073
	N0
	N1	1.53	1.20–1.96	<0.001
	N2	1.96	1.42–2.69	<0.001	840
	N3	1.39	0.34–5.59	0.646
	Nx	1.29	0.57–2.92	0.538	840
	M0
	M1	2.12	1.31–3.43	0.002	834
	Mx	1.08	0.81–1.43	0.598	834
	PhenoTIL
	Low Risk	1.06	0.78–1.44	0.688	849
D6	Gender
	Male	0.96	0.29–3.21	0.946	21
	Female
	PhenoTIL
	Low Risk	5.83	1.53–22.26	0.01
D7	Gender
	Male	2	1.14–3.52	0.0016	93
	Female
	Clinical stage
	I
	II	1.34	0.36–4.99	0.665	43
	III	2.76	0.90–8.52	0.077
	IV	2.64	0.48–14.44	0.263	43
	PhenoTIL
	Low Risk	0.53	0.29–0.97	0.041	93

Values in bold are statistically significant by two-tailed test (P < 0.05).

Back to article page

Table 2 Multivariable analysis of OS with PhenoTIL (MAD + MSCC) and clinical variables for each cohort (D1, D2, D3, D4, D5, D6, D7).

Search

Quick links